The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Challenges and future prospects of antibiotic therapy: from peptides to phages utilization
Open accessAbstract
Bacterial infections are raising serious concern across the globe. The effectiveness of conventional antibiotics is decreasing due to global emergence of multi-drug-resistant (MDR) bacterial pathogens. This process seems to be primarily caused by an indiscriminate and inappropriate use of antibiotics in non-infected patients and in the food industry. New classes of antibiotics with different actions against MDR pathogens need to be developed urgently. In this context, this review focuses on several ways and future directions to search for the next generation of safe and effective antibiotics compounds including antimicrobial peptides, phage therapy, phytochemicals, metalloantibiotics, lipopolysaccharide, and efflux pump inhibitors to control the infections caused by MDR pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plant Products as Antimicrobial Agents
Cowan, M. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.564 · Cited by 9,043
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
Brogden, K. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1098 · Cited by 5,829
Defensins: antimicrobial peptides of innate immunity
Ganz, T. (2003) · Nature Reviews Immunology · doi:10.1038/nri1180 · Cited by 3,066
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556 · cited 2×
“Rifampin, an RNAP inhibitor in clinical utilization is capable of binds to the β-subunit of RNAP within the DNA/RNA channel and blocks the RNA elongation when the transcript converts two to three nucleotides in length (Campbell et al., 2001).”
BackgroundClinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria
Piddock, L. J. V. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.382-402.2006 · Cited by 1,231 · cited 1×
“…and function, efflux pumps are subdivided into five classes: SMR pumps of the drug/metabolite transporters (DMTs) superfamily, ABC, RND, MFS, and MATE transporters of the multi-drug/oligosaccharidyl-lipid/polysaccharide flippases (MOP) superfamily (Piddock, 2006; Bhardwaj and Mohanty, 2012).”
BackgroundCationic peptides: effectors in innate immunity and novel antimicrobials
Hancock, R. E. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00092-5 · Cited by 978 · cited 2×
“Additionally, the generation of AMP prodrug candidates has also been focused (Hancock, 2001; Stella, 2004; Gordon et al., 2005; Desgranges et al., 2012).”
Background
Cited by
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00539 · Cited by 1,644
Roy, A., Bulut, O., Some, S., Mandal, A. K., & Yilmaz, M. D. (2019) · RSC Advances · doi:10.1039/c8ra08982e · Cited by 1,059
Self-citationTerpene Derivatives as a Potential Agent against Antimicrobial Resistance (AMR) Pathogens
Mahizan, N. A., Yang, S.-K., Moo, C.-L., Song, A. A.-L., Chong, C.-M., Chong, C.-W., Abushelaibi, A., Lim, S.-H. E., & Lai, K.-S. (2019) · Molecules · doi:10.3390/molecules24142631 · Cited by 473
Borrelli, L., Varriale, L., Dipineto, L., Pace, A., Menna, L. F., & Fioretti, A. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.620798 · Cited by 175
Interaction of phages, bacteria, and the human immune system: Evolutionary changes in phage therapy
Jariah, R. O. A., & Hakim, M. S. (2019) · Reviews in Medical Virology · doi:10.1002/rmv.2055 · Cited by 40
Metadata
- Authors
- Mandal, S. M., Roy, A., Ghosh, A. K., Hazra, T. K., Basak, A., & Franco, O. L.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2014-05-13
- Volume
- 5
- Pages
- 105-105
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W1986529353
- Cited by
- 159
- References
- 6
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Challenges and future prospects of antibiotic therapy: from peptides to phages utilization. https://app.cochat.ai/papers/10.3389/fphar.2014.00105
- The paper
- Mandal, S. M., Roy, A., Ghosh, A. K., Hazra, T. K., Basak, A., & Franco, O. L. (2014). Challenges and future prospects of antibiotic therapy: from peptides to phages utilization. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2014.00105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.